Interestingly, myostatin and follistatin, a myostatin antagonist, were both found to be increased in mouse models of SMA suggesting a possible compensatory attempt by the animal to minimize muscle size loss (Sumner et al., 2009). The gene discussed is FST; the disease is proximal spinal muscular atrophy.